Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 21512141.
- Also identified by DOI 10.1158/0008-5472.CAN-10-4463 and PMC identifier 3107361.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Mutated BRAF is detected in approximately 45% of papillary thyroid carcinomas (PTC). To model PTC, we bred mice with adult-onset, thyrocyte-specific expression of BRAF(V600E). One month following BRAF(V600E) expression, mice displayed increased thyroid size, widespread alterations in thyroid architecture, and dramatic hypothyroidism. Over 1 year, without any deliberate manipulation of tumor suppressor genes, all mice developed PTC displaying nuclear atypia and marker expression characteristic of the human disease. Pharmacologic inhibition of MEK1/2 led to decreased thyroid size, restoration of thyroid form and function, and inhibition of tumorigenesis. Mice with BRAF(V600E)-induced PTC will provide an excellent system to study thyroid tumor initiation and progression and the evaluation of inhibitors of oncogenic BRAF signaling.
Medical subject headings
- Cell Transformation, Neoplastic
- Mutation
- Proto-Oncogene Proteins B-raf
- Thyroid Neoplasms